Logo image of NGM

NGM BIOPHARMACEUTICALS INC (NGM) Stock Fundamental Analysis

NASDAQ:NGM - Nasdaq - US62921N1054 - Common Stock - Currency: USD

1.54  -0.02 (-1.28%)

After market: 1.55 +0.01 (+0.65%)

Fundamental Rating

3

Overall NGM gets a fundamental rating of 3 out of 10. We evaluated NGM against 195 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for NGM as it has an excellent financial health rating, but there are worries on the profitability. NGM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NGM has reported negative net income.
NGM had a negative operating cash flow in the past year.
NGM had negative earnings in each of the past 5 years.
NGM had a negative operating cash flow in each of the past 5 years.
NGM Yearly Net Income VS EBIT VS OCF VS FCFNGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -84.31%, NGM is not doing good in the industry: 74.87% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -95.79%, NGM is in line with its industry, outperforming 40.20% of the companies in the same industry.
Industry RankSector Rank
ROA -84.31%
ROE -95.79%
ROIC N/A
ROA(3y)-55.71%
ROA(5y)-41.91%
ROE(3y)-64.77%
ROE(5y)-48.77%
ROIC(3y)N/A
ROIC(5y)N/A
NGM Yearly ROA, ROE, ROICNGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NGM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGM Yearly Profit, Operating, Gross MarginsNGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

7

2. Health

2.1 Basic Checks

NGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NGM has more shares outstanding
NGM has more shares outstanding than it did 5 years ago.
NGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NGM Yearly Shares OutstandingNGM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
NGM Yearly Total Debt VS Total AssetsNGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

NGM has an Altman-Z score of -4.16. This is a bad value and indicates that NGM is not financially healthy and even has some risk of bankruptcy.
NGM has a worse Altman-Z score (-4.16) than 61.81% of its industry peers.
NGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.16
ROIC/WACCN/A
WACC9.2%
NGM Yearly LT Debt VS Equity VS FCFNGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 7.79 indicates that NGM has no problem at all paying its short term obligations.
The Current ratio of NGM (7.79) is better than 79.90% of its industry peers.
A Quick Ratio of 7.79 indicates that NGM has no problem at all paying its short term obligations.
The Quick ratio of NGM (7.79) is better than 80.40% of its industry peers.
Industry RankSector Rank
Current Ratio 7.79
Quick Ratio 7.79
NGM Yearly Current Assets VS Current LiabilitesNGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

NGM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.10%, which is quite good.
NGM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.02%.
The Revenue for NGM have been decreasing by -47.30% on average. This is quite bad
EPS 1Y (TTM)16.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)-92.02%
Revenue growth 3Y-63.03%
Revenue growth 5Y-47.3%
Sales Q2Q%-99.09%

3.2 Future

The Earnings Per Share is expected to grow by 6.98% on average over the next years.
Based on estimates for the next years, NGM will show a very strong growth in Revenue. The Revenue will grow by 69.25% on average per year.
EPS Next Y29.44%
EPS Next 2Y20.23%
EPS Next 3Y11.9%
EPS Next 5Y6.98%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y94.76%
Revenue Next 5Y69.25%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NGM Yearly Revenue VS EstimatesNGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2026 2027 2028 2029 2030 100M 200M 300M
NGM Yearly EPS VS EstimatesNGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NGM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGM Price Earnings VS Forward Price EarningsNGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGM Per share dataNGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.23%
EPS Next 3Y11.9%

More info and screens

0

5. Dividend

5.1 Amount

NGM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NGM BIOPHARMACEUTICALS INC

NASDAQ:NGM (4/4/2024, 8:17:51 PM)

After market: 1.55 +0.01 (+0.65%)

1.54

-0.02 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11 2024-03-11/amc
Earnings (Next)05-02 2024-05-02/amc
Inst Owners3.6%
Inst Owner Change0%
Ins Owners1.26%
Ins Owner Change0%
Market Cap128.53M
Analysts49.09
Price Target1.7 (10.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.62%
Min EPS beat(2)16.9%
Max EPS beat(2)18.33%
EPS beat(4)3
Avg EPS beat(4)8.18%
Min EPS beat(4)-11.04%
Max EPS beat(4)18.33%
EPS beat(8)6
Avg EPS beat(8)6.31%
EPS beat(12)8
Avg EPS beat(12)3.05%
EPS beat(16)9
Avg EPS beat(16)1.01%
Revenue beat(2)0
Avg Revenue beat(2)-73.67%
Min Revenue beat(2)-76.61%
Max Revenue beat(2)-70.73%
Revenue beat(4)0
Avg Revenue beat(4)-67.12%
Min Revenue beat(4)-76.61%
Max Revenue beat(4)-57.45%
Revenue beat(8)3
Avg Revenue beat(8)-14.9%
Revenue beat(12)4
Avg Revenue beat(12)-13.87%
Revenue beat(16)6
Avg Revenue beat(16)-10.32%
PT rev (1m)-60.88%
PT rev (3m)-60.88%
EPS NQ rev (1m)-27.96%
EPS NQ rev (3m)-27.96%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.11
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.6
FCFYN/A
OCF(TTM)-1.58
OCFYN/A
SpS0.05
BVpS1.78
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.31%
ROE -95.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.71%
ROA(5y)-41.91%
ROE(3y)-64.77%
ROE(5y)-48.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.37%
Cap/Sales 28.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.79
Quick Ratio 7.79
Altman-Z -4.16
F-Score3
WACC9.2%
ROIC/WACCN/A
Cap/Depr(3y)43.33%
Cap/Depr(5y)40.9%
Cap/Sales(3y)11.29%
Cap/Sales(5y)7.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y29.44%
EPS Next 2Y20.23%
EPS Next 3Y11.9%
EPS Next 5Y6.98%
Revenue 1Y (TTM)-92.02%
Revenue growth 3Y-63.03%
Revenue growth 5Y-47.3%
Sales Q2Q%-99.09%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y94.76%
Revenue Next 5Y69.25%
EBIT growth 1Y8.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y8.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.47%
OCF growth 3YN/A
OCF growth 5YN/A